OrthoPediatrics Raises Full-Year Revenue Guidance Following Q3 2026 Earnings
OrthoPediatrics (KIDS) reported strong third-quarter 2026 results, highlighted by an upward revision of its full-year revenue guidance to a range of $270 million to $273 million. The company's growth is being driven by a 'product super cycle' involving new pediatric surgical technologies like the 3P Hip plating system, which command higher average selling prices and increase demand for existing hospital inventory. Beyond surgical implants, the company is expanding its total addressable market through its Specialty Bracing franchise (OPSB), which now operates in over 60 clinics. This non-surgical segment offers high profit margins and faster cash returns due to lower capital requirements. Additionally, disciplined capital allocation regarding surgical instrument sets has successfully transitioned the company into positive free cash flow territory.
Tickers: $KIDS
Topics: free cash flow product launch quarterly earnings revenue guidance